Given the increased number of hospitals worldwide, the hospital pharmacy segment has taken the lead in terms of distribution channel. Furthermore, antimalarial pharmaceuticals are prescription-only medications that are usually prescribed by the specialized healthcare professionals available in hospitals, driving the expansion of this category. In contrast, the e-commerce industry is predicted to develop at the quickest rate throughout the projection period, owing to an increase in internet usage around the world.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-malaria-treatment-market
The expected CAGR of Malaria Treatment Market is tend to be around 6.6% in the mentioned forecast period of 2023-2030. The market value is USD 647.13 million in 2022, and it would grow up to USD 1,079.07 million by 2030. The high prevalence of malaria in developing and poor countries, increased government awareness programs, increased research for novel medications and innovative combination therapies, and other reasons are driving the expansion of anti-malarial drugs.
Growing disease burden is expected to drive the market's growth rate
Between 2010 and 2018, significant scaling-up of malaria interventions helped to reduce malaria case incidence and fatality rates by 19% and 39%, respectively. As a result, the expanding malaria patient pool burden in both developed and developing countries is expected to drive up demand for malaria treatment products. As a result, it will contribute to the expansion of the worldwide malaria market. Malaria's high incidence and disease burden are expected to be important driving factors in the growth of the worldwide malaria treatment industry.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015- 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Agent (Plasmodium Falciparum, P. Vivax, P. Ovale, P. Malariae and P. Knowlelsi), Type (Medication and Vaccination), Treatment Type (Suppressive Treatment and Radical Treatment), Drug Type (Branded and Generics), Route of Administration (Oral and Parenteral), End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Actiza Pharmaceutical Private Limited (India), Amneal Pharmaceuticals LLC. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Cipla Inc. (India), Lupin (India), Ipca Laboratories Ltd (India), Mylan N.V. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Zydus Group (India), MMV (Switzerland), Novartis AG (Switzerland), Sumaya Biotech (Germany), Taj Pharmaceuticals Limited (India), OSIVAX (France), Strides Pharma Science Limited (India)
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
Global malaria treatment market is categorized into seven notable segments which are based on the agent, type, treatment type, drug type, route of administration, end user and distribution channel.
- On the basis of agent, the global malaria treatment market is segmented into plasmodium falciparum, P. vivax, P. ovale, P. malariae and P. knowlelsi. Plasmodium falciparum segment is dominating in the malaria treatment market and is expected to reach USD 888,377.82 thousand by 2030 due to its rapid transmission. Additionally, climate condition and humidity of Sub-Saharan Africa is enhancing the transmission of malaria by the virtue of plasmodium falciparum.
- On the basis of type, the global malaria treatment market is segmented into medication and vaccination. Medication segment is dominating in the malaria treatment market and is estimated to reach USD 814,678.23 thousand by 2030 as it is cost effective, easily accessible and is a primarily treatment for the malaria patient pool.
- On the basis of treatment type, the global malaria treatment market is segmented into suppressive treatment and radical treatment. Suppressive treatment segment is dominating in the malaria treatment market with the market share of 87.87% and is estimated to reach USD 945,788.70 thousand by 2030 because it is considered to be the primary and fundamental treatment. Moreover, enormous demand of suppressive treatment worldwide acts as another driving factor for the malaria treatment market growth.
- On the basis of drug type, the global malaria treatment market is segmented into branded and generics. Generics segment is dominating in the malaria treatment market and is estimated to reach USD 820,953.60 thousand by 2030 because it is cost-effective in comparison to the branded drugs. The growing demand of generics dugs from low and middle income countries act as another driving factor for the malaria treatment market growth.
- On the basis of route of administration, the global malaria treatment market is segmented into oral and parenteral. Oral segment is dominating in the malaria treatment market and USD 844,454.79 thousand by 2030 because it is considered the first line of therapy. Moreover, low manufacturing cost of tablets, capsules and other orally administered drugs act as another driving factor for the malaria treatment market growth.
- On the basis of end user, the global malaria treatment market is segmented into hospitals, specialty clinics, home healthcare and others. Hospitals segment is dominating in the malaria treatment market and is estimated to reach USD 981,977.50 thousand by 2030 because of the increased healthcare expenditure by hospitals on advanced medical treatment.
The hospitals segment will dominate the end user segment of the malaria treatment market
The hospitals segment will emerge as the dominating segment end user segment. This is because of the growing number of hospitals in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.
- On the basis of distribution channel, the global malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies and online pharmacies. Direct tender segment is dominating in the malaria treatment market and is estimated to reach USD 708,414.46 thousand by 2030 because most of the service providers buy the product from manufacturers and it is noticed that revenue from direct sales is higher so it is influential as well as growing in the malaria treatment market.
The direct tender segment will dominate the distribution channel segment of the malaria treatment market
The direct tender segment will emerge as the dominating segment under distribution channel. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.
Major Players
Data Bridge Market Research recognizes the following companies as the major market players: Actiza Pharmaceutical Private Limited (India), Amneal Pharmaceuticals LLC. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Cipla Inc. (India), Lupin (India), Ipca Laboratories Ltd (India), Mylan N.V. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Zydus Group (India), MMV (Switzerland), Novartis AG (Switzerland), Sumaya Biotech (Germany), Taj Pharmaceuticals Limited (India), OSIVAX (France), Strides Pharma Science Limited (India).
Market Development
- In 2022, Tafenoquine, a new medicine that can cure a specific type of malaria, was licenced in Australia in March by Medicines for Malaria Venture (MMV), which collaborated with GlaxoSmithKline (GSK) to create the drug for children and teenagers. The medicine is used in conjunction with the standard malaria treatment, chloroquine.
- In 2020, =ADVANZ PHARMA Corp. Limited inked a contract in May to acquire Correvio Pharma Corp., a specialty pharmaceutical company. ADVANZ PHARMA now has a direct and immediate commercial presence in the Benelux nations, as well as Germany, France, Spain, and Italy, as a result of the acquisition.
Regional Analysis
Geographically, the countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in the malaria treatment market during the forecast period 2023-2030
Given the high prevalence of malaria vector-borne disease in North America, the region dominates the market. enhanced investment from regional governments, enhanced clinical development, and product releases are all having a favourable impact on market growth.
Asia-Pacific is estimated to be the fastest growing region in the malaria treatment market in the forecast period 2023-2030
Asia-Pacific is the fastest expanding area, with demand for malaria treatment increasing rapidly due to rising healthcare costs and increased knowledge of malaria vector-borne disease symptoms.
For more detailed information about the malaria treatment market report, click here – https://www.databridgemarketresearch.com/reports/global-malaria-treatment-market
